Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine −

NurExone Announces Closing of Non-Brokered Private Placement

Dilutive financing at a discount underscores cash burn concerns in pre-revenue exosome developer

By The Northwire Desk — AI Analysis Jun 30, 2026 · 08:31 NRX · 0.57 NurExone Biologic Inc.
Executive Summary
  • NurExone Biologic Inc. closed a non-brokered private placement of 1,012,573 units.
  • Pricing was set at C$0.62 per unit, generating gross proceeds of approximately C$627,795.26 (roughly $460,000 USD).
  • Proceeds are designated for general working capital purposes.
  • Each unit consists of one common share and one common share purchase warrant.
  • Warrant terms include a C$0.78 exercise price, a 36-month term, and an acceleration clause if the TSXV VWAP reaches C$1.55 for 20 consecutive days.
  • No insiders participated, and no finder's fees were paid.
  • Closing is subject to TSXV approval and carries a statutory hold period of four months and one day.
Material Impact
  • The capital raise is small relative to the company's operating burn and provides only a short-term cash bridge.
  • The offering price of C$0.62 (~$0.45 USD) represents a ~20% discount to the recent trading range of $0.55–$0.57 USD, indicating management's need to attract capital at a depressed valuation.
  • The issuance dilutes existing shareholders by approximately 1.1% on a fully diluted basis (including warrants).
  • The transaction does not alter the company's strategic direction, clinical timeline, or commercial roadmap. It merely extends the cash runway by a few months.
  • Given the explicit going concern warning in the Q1 2026 MD&A, this financing is a predictable, defensive measure rather than a transformative event.
NRX · Price
Company Overview
  • NurExone Biologic Inc. is a pre-revenue biotechnology company focused on exosome-based therapeutics.
  • Lead candidate: ExoPTEN, an exosome-siRNA delivery system targeting acute spinal cord injury and optic nerve damage.
  • Dual-track strategy: advancing regulated therapeutic development (ExoPTEN) while commercializing naive MSC-derived exosomes for wellness and aesthetics through its U.S. subsidiary, Exo-Top Inc.
  • Strong intellectual property portfolio with granted patents in the U.S., Israel, Australia, and Korea.
  • Preclinical data has demonstrated dose-dependent vision recovery in glaucoma models and motor function restoration in spinal cord injury models.
  • Aiming for FDA IND submission in H2 2026 and First-in-Human trials in 2027.
Read the original news release →

More from NurExone Biologic Inc.

Jun 24, 2026 · 17:01

Early-stage exosome developer secures Mexican distribution MOU while navigating a tight cash runway and going concern warning.

M&A / Property Jun 01, 2026 · 08:02

NurExone Advances Preclinical Milestones and Secures Minor Capital, But Cash Runway Narrows as Burn Rate Accelerates

Earnings May 19, 2026 · 16:04

NurExone Expands IP Portfolio with South Korea Patent Grant Amidst Manufacturing Push

Other May 14, 2026 · 16:05

NurExone’s EU Program Nod Underscores Exosome Platform’s Promise, But Cash Burn Keeps Investors on Edge

Other Apr 27, 2026 · 16:03

Patent Portfolio Expansion Masks Underlying Liquidity Constraints in Exosome Developer

M&A / Property Apr 16, 2026 · 09:15

NurExone Extends Runway Amid Rising Burn Rate as IND Prep Continues

Earnings